Intermittent LHRH therapy in the management of castrate-resistant prostate cancer (CRPCa):results of a multi-institutional randomized prospective clinical trial

Organ, Michael, Wood, Lori, Wilke, Derek, Skedgel, Chris, Cheng, Tina, North, Scott, Thompson, Kara, Winch, Susan and Rendon, Ricardo (2013) Intermittent LHRH therapy in the management of castrate-resistant prostate cancer (CRPCa):results of a multi-institutional randomized prospective clinical trial. American Journal of Clinical Oncology, 36 (6). pp. 601-605. ISSN 1537-453X

Full text not available from this repository. (Request a copy)

Abstract

Patients who develop castration-resistant prostate cancer (CRPCa) typically continue on androgen deprivation therapy (ADT). Whether these patients need to remain on ADT has not been well studied. We conducted a multicenter randomized trial to compare an intermittent versus continuous approach to ADT in CRPCa patients. Overall survival, health-related quality of life (QOL), and cost were the main endpoints.

Item Type:	Article
Uncontrolled Keywords:	aged,aged, 80 and over,costs and cost analysis,follow-up studies,gonadotropin-releasing hormone,humans,male,middle aged,prostate-specific antigen,prostatic neoplasms, castration-resistant,quality of life,questionnaires,testosterone,treatment outcome,sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Health Economics Faculty of Medicine and Health Sciences > Research Groups > Public Health and Health Services Research (former - to 2023)
Depositing User:	Pure Connector
Date Deposited:	03 Feb 2015 13:04
Last Modified:	06 Feb 2025 05:27
URI:	https://ueaeprints.uea.ac.uk/id/eprint/51928
DOI:	10.1097/COC.0b013e31825d5664

Actions (login required)

View Item